Clinical Rheumatology

, Volume 37, Issue 4, pp 1119–1122 | Cite as

Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report

  • Samuel Deshayes
  • Nicolas Martin Silva
  • Valérie Chatelet
  • Sylvain Chantepie
  • Moglie Le Quintrec
  • François Comoz
  • Frank Bridoux
  • Marie-Agnès Dragon-Durey
  • Achille Aouba
Case Based Review


B-cell clones can produce a monoclonal immunoglobulin, which may be responsible for visceral involvements. Kidney involvement is frequent, affecting 20 to 50% of patients with multiple myeloma. One mechanism underlying this involvement is a dysregulation of the complement alternative pathway, leading to C3 glomerulopathies. We report a patient who had a multiple myeloma, C3 glomerulopathy related to factor H autoantibody, and digital ischemia, who was treated successfully with eculizumab, an anti-complement therapy, without any relapse in 2 years of follow-up.


C3 glomerulopathies Digital ischemia Eculizumab Factor H antibody 


Compliance with ethical standards




  1. 1.
    Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH, on behalf of the International Kidney and Monoclonal Gammopathy Research Group (2015) Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 87:698–711. CrossRefPubMedGoogle Scholar
  2. 2.
    Blanc C, Togarsimalemath SK, Chauvet S, le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA (2015) Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 194:5129–5138. CrossRefPubMedGoogle Scholar
  3. 3.
    Le Quintrec M, Lionet A, Kandel C et al (2015) Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65:484–489. CrossRefPubMedGoogle Scholar
  4. 4.
    Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F (2017) Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129:1437–1447. CrossRefPubMedGoogle Scholar
  5. 5.
    Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C (2015) Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgAλ antibody. Am J Kidney Dis 66:331–336. CrossRefPubMedGoogle Scholar
  6. 6.
    Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F (2013) Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 131:e331–e335. CrossRefPubMedGoogle Scholar
  7. 7.
    Sathe KP, Ohri A, Mishra A, Ali U (2016) Digital gangrene in a child with atypical hemolytic uremic syndrome associated with anti-factor H antibodies. Indian J Nephrol 26:231–232. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ferluga J, Kishore U, Sim RB (2014) A potential anti-coagulant role of complement factor H. Mol Immunol 59:188–193. CrossRefPubMedGoogle Scholar
  9. 9.
    Turner N, Nolasco L, Nolasco J, Sartain S, Moake J (2014) Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin Thromb Hemost 40:544–550. CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Samuel Deshayes
    • 1
  • Nicolas Martin Silva
    • 1
  • Valérie Chatelet
    • 2
  • Sylvain Chantepie
    • 3
  • Moglie Le Quintrec
    • 4
  • François Comoz
    • 5
  • Frank Bridoux
    • 6
  • Marie-Agnès Dragon-Durey
    • 7
  • Achille Aouba
    • 1
  1. 1.Department of Internal Medicine and Clinical ImmunologyCHU Côte de Nacre—Université Basse NormandieCaenFrance
  2. 2.Department of NephrologyCHU de CaenCaenFrance
  3. 3.Department of Clinical HematologyCHU de CaenCaenFrance
  4. 4.Service de Transplantation et NéphrologieCHU de LapeyronieMontpellierFrance
  5. 5.Department of AnatomopathologyCHU de CaenCaenFrance
  6. 6.Department of Nephrology and Transplantation and Centre national de référence maladies rares: amylose AL et autres maladies à depôts d’immunoglobulines monoclonalesCHU de PoitiersPoitiersFrance
  7. 7.Department of Biological Immunology, Assistance Publique-Hôpitaux de ParisHôpital Européen Georges PompidouParisFrance

Personalised recommendations